Impact of donor and recipient Epstein-Barr Virus serostatus on outcomes of allogeneic hematopoietic cell transplantation: a systematic review and meta-analysis.

Szczegóły
Abstrakt

Tytuł:: Impact of donor and recipient Epstein-Barr Virus serostatus on outcomes of allogeneic hematopoietic cell transplantation: a systematic review and meta-analysis.
Autorzy:: Kołodziejczak M; Department of Anesthesiology and Intensive Care, Collegium Medicum Bydgoszcz, Nicolaus Copernicus University Torun, Antoni Jurasz University Hospital No.1, Bydgoszcz, Poland.
Gil L; Department of Hematology and Hematopoietic Cell Transplantation, Medical University, Poznan, Poland.
de la Camara R; Department of Hematology, Hospital de la Princesa, Madrid, Spain.
Styczyński J; Department of Pediatric Hematology and Oncology, Collegium Medicum Bydgoszcz, Nicolaus Copernicus University Torun, Antoni Jurasz University Hospital No.1, ul. Sklodowskiej-Curie 9, 85-094, Bydgoszcz, Poland. .
Corporate Authors:: Infectious Diseases Working Party, European Society for Blood and Marrow Transplantation
Źródło:: Annals of hematology [Ann Hematol] 2021 Mar; Vol. 100 (3), pp. 763-777. Date of Electronic Publication: 2021 Jan 25.
Typ publikacji:: Journal Article; Meta-Analysis; Systematic Review
Język:: English
Imprint Name(s):: Publication: Berlin : Springer Verlag
Original Publication: Berlin ; New York : Springer International, c1991-
MeSH Terms:: Hematopoietic Stem Cell Transplantation*/adverse effects
Hematopoietic Stem Cell Transplantation*/mortality
Hematopoietic Stem Cell Transplantation*/statistics & numerical data
Epstein-Barr Virus Infections/*epidemiology
Hematologic Neoplasms/*epidemiology
Hematologic Neoplasms/*therapy
Tissue Donors/*statistics & numerical data
Transplant Recipients/*statistics & numerical data
Adolescent ; Adult ; Aged ; Epstein-Barr Virus Infections/complications ; Epstein-Barr Virus Infections/diagnosis ; Female ; Graft vs Host Disease/diagnosis ; Graft vs Host Disease/etiology ; Graft vs Host Disease/mortality ; Hematologic Neoplasms/complications ; Hematologic Neoplasms/diagnosis ; Herpesvirus 4, Human/physiology ; Humans ; Male ; Middle Aged ; Prognosis ; Recurrence ; Seroepidemiologic Studies ; Survival Analysis ; Transplantation, Homologous/adverse effects ; Transplantation, Homologous/mortality ; Treatment Outcome ; Young Adult
References:: Haematologica. 2016 Jul;101(7):803-11. (PMID: 27365460)
Haematologica. 2014 Feb;99(2):346-52. (PMID: 24056821)
Biol Blood Marrow Transplant. 2010 Feb;16(2):215-22. (PMID: 19786112)
Bone Marrow Transplant. 2018 Dec;53(12):1508-1517. (PMID: 29795424)
Psychol Bull. 1968 Apr;69(4):269-277. (PMID: 5659656)
Biol Blood Marrow Transplant. 2018 Nov;24(11):2324-2336. (PMID: 29684567)
N Engl J Med. 2000 Aug 17;343(7):481-92. (PMID: 10944566)
Blood. 1986 Apr;67(4):1162-7. (PMID: 3006831)
J Clin Epidemiol. 2009 Oct;62(10):1006-12. (PMID: 19631508)
Control Clin Trials. 1986 Sep;7(3):177-88. (PMID: 3802833)
J Infect Dis. 2013 Jun 15;207(12):1787-9. (PMID: 23493726)
Clin Infect Dis. 2014 Aug 15;59(4):473-81. (PMID: 24850801)
Blood. 2003 Dec 15;102(13):4255-60. (PMID: 12933590)
Bone Marrow Transplant. 2008 Nov;42(10):673-7. (PMID: 18695666)
Blood. 2013 Nov 7;122(19):3359-64. (PMID: 24037724)
J Clin Oncol. 2016 Jul 1;34(19):2212-20. (PMID: 27091716)
Bone Marrow Transplant. 2019 Dec;54(12):2060-2071. (PMID: 31363166)
Haematologica. 2006 Aug;91(8):1059-67. (PMID: 16885046)
Transplantation. 1974 Oct;18(4):295-304. (PMID: 4153799)
Lancet Haematol. 2016 Mar;3(3):e119-27. (PMID: 26947200)
BMJ. 2003 Sep 6;327(7414):557-60. (PMID: 12958120)
Contributed Indexing:: Keywords: EBV; Epstein-Barr virus; GVHD; Graft-versus-host disease; HCT; Hematopoietic cell transplantation; Non-relapse mortality; Overall survival; Relapse incidence; Relapse-free survival
Entry Date(s):: Date Created: 20210125 Date Completed: 20210305 Latest Revision: 20210316
Update Code:: 20240105
PubMed Central ID:: PMC7914248
DOI:: 10.1007/s00277-021-04428-9
PMID:: 33491135
: Czasopismo naukowe

Full Text Finder

Allogeneic hematopoietic cell transplant (allo-HCT) is a potentially curative therapeutic strategy that showed encouraging long-term outcomes in hematological diseases. A number of factors can influence post-transplant clinical outcomes. While Epstein-Barr virus (EBV) constitutes a trigger for development of various adverse conditions, no clinical study yet has been powered to assess the effect of EBV serostatus on the clinical outcomes in allo-HCT population. To systematically summarize and analyze the impact of donor and recipient EBV serostatus on transplant outcomes in allo-HCT recipients, meta-analyses were conducted. Selected endpoints were overall survival (OS), relapse-free survival (RFS), relapse incidence (RI), non-relapse mortality (NRM), acute graft-versus-host disease (aGVHD), chronic graft-versus-host disease (cGVHD), and de novo cGVHD. Three studies with 26,650 patients, transplanted for acute leukemias, lymphomas, chronic hematological malignancies, or non-malignant hematological diseases were included in the meta-analysis. In the whole population, with a total of 53,300 donors and recipients, the rate of EBV seropositivity was 85.1%, including 86.6% and 83.6% among transplant recipients and healthy donors, respectively. Donor EBV seropositivity increased the risk of cGVHD by 17%, de novo cGVHD by 14%, and aGHVD by 5%. Recipient EBV seropositivity increased the risk of cGVHD by 12%, de novo cGVHD by 17%; increased NRM by 11%, increased RI by 11%, decreased OS by 14%, and decreased RFS by 11%. In performed meta-analyses, donor and recipient EBV seropositivity was found to have a significant impact on transplant outcomes in patients after allo-HCT.

Informacja